Institution
Paris Descartes University
Government•Paris, France•
About: Paris Descartes University is a government organization based out in Paris, France. It is known for research contribution in the topics: Population & Immune system. The organization has 20987 authors who have published 37456 publications receiving 1206222 citations. The organization is also known as: Université Paris V-Descartes & Université de Paris V.
Topics: Population, Immune system, Cancer, Transplantation, Pregnancy
Papers published on a yearly basis
Papers
More filters
TL;DR: The regulation of autophagy in the course of cellular immune responses is discussed and its impact on the immunogenicity of antigen-donor cells and on the activity of antibody-presenting cells and T lymphocytes is emphasized.
362 citations
TL;DR: The biology of the most abundant miRNA in human liver, miR-122, is reviewed, and the diversity of its roles in the liver is considered, and some possible therapeutic opportunities for exploiting miRNAs in the different settings of liver diseases are considered.
361 citations
National and Kapodistrian University of Athens1, Gunma University2, University of Manchester3, University of Wisconsin-Madison4, University of Southampton5, The Chinese University of Hong Kong6, University of Cape Town7, Swiss Institute of Allergy and Asthma Research8, Washington University in St. Louis9, University of Padua10, National University of Singapore11, Paris Descartes University12, University of Verona13, Duke University14, Creighton University15, Pontifical Catholic University of Chile16, Ain Shams University17, National Health Service18, Medical University of Vienna19, Karolinska Institutet20, University of Virginia21, University of Ulsan22, Chang Gung University23, Stellenbosch University24, Medical University of Łódź25, Charité26, University of South Florida27, Sungkyunkwan University28, University of Colorado Denver29, Nippon Medical School30, Charles University in Prague31, Children's Memorial Hospital32, Royal Children's Hospital33, Federal University of Paraná34, Children's Mercy Hospital35, University of Queensland36, Pontifícia Universidade Católica do Rio Grande do Sul37, Princess Margaret Hospital for Children38, University of Denver39, University of Turku40, Mahidol University41, Nova Southeastern University42, University of Gothenburg43, University of Zurich44, Kaiser Permanente45
TL;DR: The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference.
Abstract: Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.
360 citations
TL;DR: The potential uses of polysaccharides, the limits and the future developments in this field with these natural polymers are reviewed.
359 citations
Paris Descartes University1, French Institute of Health and Medical Research2, university of lille3, Rappaport Faculty of Medicine4, University of Lübeck5, University of Padua6, University of Pécs7, University of the Witwatersrand8, University of Giessen9, University of Verona10, University of Zurich11, University of Bari12, Lund University13, Charles University in Prague14, Marche Polytechnic University15, University of Belgrade16, Sapienza University of Rome17, Carol Davila University of Medicine and Pharmacy18, University of Debrecen19, University of Basel20, Ghent University21, Federal University of Paraná22, University of Milan23, Policlinico Umberto I24, Katholieke Universiteit Leuven25, University of Waikato26, University of Otago27, University of Alabama28, University Hospital Centre Zagreb29, James Cook University Hospital30, Technische Universität München31, University of Buenos Aires32, Medical University of Białystok33, University of Florence34
TL;DR: Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality.
Abstract: Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients’ survival.
358 citations
Authors
Showing all 21023 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Guido Kroemer | 236 | 1404 | 246571 |
| Cyrus Cooper | 204 | 1869 | 206782 |
| Jean-Laurent Casanova | 144 | 842 | 76173 |
| Alain Fischer | 143 | 770 | 81680 |
| Maxime Dougados | 134 | 1054 | 69979 |
| Carlos López-Otín | 126 | 494 | 83933 |
| Giuseppe Viale | 123 | 740 | 72799 |
| Thierry Poynard | 119 | 668 | 64548 |
| Lorenzo Galluzzi | 118 | 477 | 71436 |
| Shahrokh F. Shariat | 118 | 1637 | 58900 |
| Richard E. Tremblay | 116 | 685 | 45844 |
| Olivier Hermine | 111 | 1026 | 43779 |
| Yehezkel Ben-Ari | 110 | 459 | 44293 |
| Loïc Guillevin | 108 | 800 | 51085 |
| Gérard Socié | 107 | 920 | 44186 |